Terapevticheskii arkhivTerapevticheskii arkhiv0040-36602309-5342LLC Obyedinennaya Redaktsiya29975Efficacy and tolerance of stepwise therapy withmovalis in rheumatic diseasesTsvetkovaE S-151220047912788109042020Copyright © 2004, Consilium Medicum2004lecturerheumatic diseasesstepwise therapymovalisлекцияревматические болезниступенчатая терапияингибитор ЦОГ-2мовалис[Wallace G. L. Nonsteroidal anti-inflammatory drugs and gastoenteropathy: the second hundred years. Gastroenterology 1997; 112: 1000-1016.][Malmberg А. В., Yaksh T. L. Antinociceptive actions of spinalnonsteroidal anti-inflammatory agents on the formalin test in the rat. J. Pharmacol. Exp. Ther. 1992; 263: 136-146.][Tilley S. L., Coffman T. M., Roller В. М. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J. Clin. Invest. 2001; 108: 15- 23.][Vane G. R., Bakchle Y. S., Bolting R. M. Cyclooxygenase 1 and 2. Annu. Rev. Pharmacol. Toxicol. 1998; 38: 97-120.][Насонов Е. Л., Цветкова Е. С. Селективные ингибиторы циклооксигеназы-2: новые перспективы лечения заболеваний человека. Тер. арх. 1998; 5: 8-14.][Насонов Е. Л. Нестероидные противовоспалительные препараты (перспективы применения в медицине). М.; 2000.][Needleman P., Isakson P. The discovery and function of COX-J. Rheumatol. 1997; 24(49): 6-8.][Del Tacca M., Colucci R., Fornati M., Blandizzi С. Efficacy and tolerability of Meloxicam: nonsteroidal anti-inflammatory drug - selective inhibitor of a cyclooxygenase-2. Clin. Drug Invest. 2002; 22 (12): 799-818.][Davies N. M., Skjodt N. M. Clinical pharmacokinetics of moxicam: a cyclooxygenase-2 preferential nonsteroidal antiflammatory drug. Clin. Pharmacokinet. 1999; 36: 115-126.][Lapicque F., Vergne P., Gouzcau J.-I. et al. Articular diffusi of Meloxicam after a single oral dose: relationship to cycloc ygenaze inhibition in synovial cells. Clin. Pharmacokin 2000; 39: 369-382.][Cacace L. Elevated serum CPK after drug injections. N. En J. Med. 1972;287:309-310.][Combe В., Velicitat P., Garson N. et al. Comparison of intimuscular and oral meloxicam in rheumatoid arthritis patien Inflamm. Res. 2001; 50 (1): S10-S16.][Auvinet В., Ziller R., Appelboom T. et al. Comparison of tonset and intensity of action of intramuscular Meloxicam aioral Meloxicam in patients with acute sciatica. Clin. The 1995; 17 (6): 78-90.][Ghozlan P., Benhardt M., Velicitat P. et al. Tolerability of mutiple administration of intramuscular Meloxicam: a comparisc with of intramuscular Piroxicam in patients with rheumato arthritis or osteoarthritis. Br. J. Rheumatol. 1996; 35 (1): 51- 55.]